The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Oral Drugs for Benign Prostatic Hyperplasia Market Research Report 2025

Global Oral Drugs for Benign Prostatic Hyperplasia Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1961738

No of Pages : 89

Ask Your Query
Synopsis
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Drugs for Benign Prostatic Hyperplasia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Drugs for Benign Prostatic Hyperplasia.
Report Scope
The Oral Drugs for Benign Prostatic Hyperplasia market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Drugs for Benign Prostatic Hyperplasia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck
Segment by Type
Alpha Blockers
5-alpha Reductase Inhibitors
Others
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Drugs for Benign Prostatic Hyperplasia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Drugs for Benign Prostatic Hyperplasia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Oral Drugs for Benign Prostatic Hyperplasia Market Overview
1.1 Product Overview and Scope of Oral Drugs for Benign Prostatic Hyperplasia
1.2 Oral Drugs for Benign Prostatic Hyperplasia Segment by Type
1.2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Type (2024-2030)
1.2.2 Alpha Blockers
1.2.3 5-alpha Reductase Inhibitors
1.2.4 Others
1.3 Oral Drugs for Benign Prostatic Hyperplasia Segment by Application
1.3.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Estimates and Forecasts
1.4.1 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue 2019-2030
1.4.2 Global Oral Drugs for Benign Prostatic Hyperplasia Sales 2019-2030
1.4.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Drugs for Benign Prostatic Hyperplasia Market Competition by Manufacturers
2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Average Price by Manufacturers (2019-2024)
2.4 Global Oral Drugs for Benign Prostatic Hyperplasia Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Product Type & Application
2.7 Oral Drugs for Benign Prostatic Hyperplasia Market Competitive Situation and Trends
2.7.1 Oral Drugs for Benign Prostatic Hyperplasia Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Drugs for Benign Prostatic Hyperplasia Players Market Share by Revenue
2.7.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Drugs for Benign Prostatic Hyperplasia Retrospective Market Scenario by Region
3.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Drugs for Benign Prostatic Hyperplasia Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region: 2019-2030
3.2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region: 2019-2024
3.2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region: 2025-2030
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region: 2019-2030
3.3.1 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region: 2019-2024
3.3.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region: 2025-2030
3.4 North America Oral Drugs for Benign Prostatic Hyperplasia Market Facts & Figures by Country
3.4.1 North America Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2030)
3.4.3 North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Drugs for Benign Prostatic Hyperplasia Market Facts & Figures by Country
3.5.1 Europe Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2030)
3.5.3 Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2030)
3.6.3 Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oral Drugs for Benign Prostatic Hyperplasia Market Facts & Figures by Country
3.7.1 Latin America Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2030)
3.7.3 Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2019-2030)
4.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2019-2024)
4.1.2 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2025-2030)
4.1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2019-2030)
4.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2019-2030)
4.2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2019-2024)
4.2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2025-2030)
4.2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2019-2030)
4.3 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2019-2030)
5.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2019-2024)
5.1.2 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2025-2030)
5.1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2019-2030)
5.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2019-2030)
5.2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2019-2024)
5.2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2025-2030)
5.2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2019-2030)
5.3 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Description and Business Overview
6.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.3.5 Astellas Pharma Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.7.5 Allergan Recent Developments/Updates
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Description and Business Overview
6.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.8.5 TEVA Recent Developments/Updates
6.9 Viatris
6.9.1 Viatris Corporation Information
6.9.2 Viatris Description and Business Overview
6.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.9.5 Viatris Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Description and Business Overview
6.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Product Portfolio
6.11.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Chain Analysis
7.2 Oral Drugs for Benign Prostatic Hyperplasia Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Drugs for Benign Prostatic Hyperplasia Production Mode & Process
7.4 Oral Drugs for Benign Prostatic Hyperplasia Sales and Marketing
7.4.1 Oral Drugs for Benign Prostatic Hyperplasia Sales Channels
7.4.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors
7.5 Oral Drugs for Benign Prostatic Hyperplasia Customers
8 Oral Drugs for Benign Prostatic Hyperplasia Market Dynamics
8.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Trends
8.2 Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
8.3 Oral Drugs for Benign Prostatic Hyperplasia Market Challenges
8.4 Oral Drugs for Benign Prostatic Hyperplasia Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Oral Drugs for Benign Prostatic Hyperplasia Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oral Drugs for Benign Prostatic Hyperplasia Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oral Drugs for Benign Prostatic Hyperplasia, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Product Type & Application
Table 12. Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Drugs for Benign Prostatic Hyperplasia by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Drugs for Benign Prostatic Hyperplasia as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2019-2024) & (K Units)
Table 18. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2019-2024)
Table 19. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2025-2030) & (K Units)
Table 20. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2025-2030)
Table 21. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2019-2024)
Table 23. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2025-2030)
Table 25. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2024) & (K Units)
Table 27. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2025-2030) & (K Units)
Table 28. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2024) & (K Units)
Table 32. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2025-2030) & (K Units)
Table 33. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Type (2019-2024)
Table 51. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Type (2025-2030)
Table 52. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2019-2024)
Table 53. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2025-2030)
Table 54. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2019-2024)
Table 57. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2025-2030)
Table 58. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Application (2019-2024)
Table 61. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Application (2025-2030)
Table 62. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2019-2024)
Table 63. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2025-2030)
Table 64. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2019-2024)
Table 67. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2025-2030)
Table 68. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Application (2025-2030)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Astellas Pharma Corporation Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product
Table 84. Astellas Pharma Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Abbott Corporation Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product
Table 99. Abbott Recent Developments/Updates
Table 100. Allergan Corporation Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product
Table 104. Allergan Recent Developments/Updates
Table 105. TEVA Corporation Information
Table 106. TEVA Description and Business Overview
Table 107. TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product
Table 109. TEVA Recent Developments/Updates
Table 110. Viatris Corporation Information
Table 111. Viatris Description and Business Overview
Table 112. Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product
Table 114. Viatris Recent Developments/Updates
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product
Table 119. Novartis Recent Developments/Updates
Table 120. Merck Corporation Information
Table 121. Merck Description and Business Overview
Table 122. Merck Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Merck Oral Drugs for Benign Prostatic Hyperplasia Product
Table 124. Merck Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Oral Drugs for Benign Prostatic Hyperplasia Distributors List
Table 128. Oral Drugs for Benign Prostatic Hyperplasia Customers List
Table 129. Oral Drugs for Benign Prostatic Hyperplasia Market Trends
Table 130. Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
Table 131. Oral Drugs for Benign Prostatic Hyperplasia Market Challenges
Table 132. Oral Drugs for Benign Prostatic Hyperplasia Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Oral Drugs for Benign Prostatic Hyperplasia
Figure 2. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oral Drugs for Benign Prostatic Hyperplasia Market Share by Type in 2023 & 2030
Figure 4. Alpha Blockers Product Picture
Figure 5. 5-alpha Reductase Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Oral Drugs for Benign Prostatic Hyperplasia Market Share by Application in 2023 & 2030
Figure 9. Hospitals
Figure 10. Drugstores
Figure 11. Others
Figure 12. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size (2019-2030) & (US$ Million)
Figure 14. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (2019-2030) & (K Units)
Figure 15. Global Oral Drugs for Benign Prostatic Hyperplasia Average Price (US$/Unit) & (2019-2030)
Figure 16. Oral Drugs for Benign Prostatic Hyperplasia Report Years Considered
Figure 17. Oral Drugs for Benign Prostatic Hyperplasia Sales Share by Manufacturers in 2023
Figure 18. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Oral Drugs for Benign Prostatic Hyperplasia Players: Market Share by Revenue in 2023
Figure 20. Oral Drugs for Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2019-2030)
Figure 23. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2019-2030)
Figure 24. United States Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2019-2030)
Figure 27. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2019-2030)
Figure 28. Germany Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2019-2030)
Figure 35. China Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2019-2030)
Figure 45. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Type (2019-2030)
Figure 55. Global Revenue Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Type (2019-2030)
Figure 56. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Application (2019-2030)
Figure 58. Global Revenue Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Application (2019-2030)
Figure 59. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Application (2019-2030)
Figure 60. Oral Drugs for Benign Prostatic Hyperplasia Value Chain
Figure 61. Oral Drugs for Benign Prostatic Hyperplasia Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock